Accuray Incorporated (ARAY) SVP Sells $10,526.76 in Stock

Accuray Incorporated (NASDAQ:ARAY) SVP Alaleh Nouri sold 2,166 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.86, for a total transaction of $10,526.76. Following the transaction, the senior vice president now directly owns 207,068 shares of the company’s stock, valued at approximately $1,006,350.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Accuray Incorporated (ARAY) traded up $0.10 during trading on Monday, hitting $5.25. 1,641,800 shares of the stock traded hands, compared to its average volume of 713,905. Accuray Incorporated has a 52 week low of $3.60 and a 52 week high of $6.00. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.18%. The company had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. research analysts anticipate that Accuray Incorporated will post -0.18 EPS for the current fiscal year.

Several equities analysts recently commented on ARAY shares. Zacks Investment Research raised shares of Accuray from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Tuesday, October 24th. Jefferies Group reaffirmed a “buy” rating and set a $7.00 price target on shares of Accuray in a research report on Wednesday, August 9th. Cowen reaffirmed a “buy” rating and set a $9.00 price target on shares of Accuray in a research report on Friday, October 27th. Lake Street Capital initiated coverage on shares of Accuray in a research report on Thursday. They set a “buy” rating and a $10.00 price target for the company. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $5.00 price objective on shares of Accuray in a research report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Accuray presently has a consensus rating of “Hold” and a consensus price target of $6.82.

Several institutional investors have recently added to or reduced their stakes in ARAY. Vanguard Group Inc. boosted its stake in shares of Accuray by 4.4% in the second quarter. Vanguard Group Inc. now owns 6,728,919 shares of the medical equipment provider’s stock valued at $31,962,000 after purchasing an additional 281,789 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Accuray by 27.6% in the first quarter. Dimensional Fund Advisors LP now owns 858,013 shares of the medical equipment provider’s stock valued at $4,076,000 after purchasing an additional 185,519 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Accuray by 2.0% in the second quarter. Renaissance Technologies LLC now owns 4,391,000 shares of the medical equipment provider’s stock valued at $20,857,000 after purchasing an additional 85,400 shares during the period. PDT Partners LLC boosted its stake in shares of Accuray by 60.5% in the second quarter. PDT Partners LLC now owns 156,500 shares of the medical equipment provider’s stock valued at $743,000 after purchasing an additional 58,985 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of Accuray by 13.4% in the second quarter. Russell Investments Group Ltd. now owns 773,480 shares of the medical equipment provider’s stock valued at $3,673,000 after purchasing an additional 91,267 shares during the period. 78.86% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/12/04/accuray-incorporated-aray-svp-sells-10526-76-in-stock.html.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

What are top analysts saying about Accuray Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Accuray Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit